Menu
ncarol.com
  • Home
  • Books
  • Health
  • Book Release
  • Manufacturing
  • Business
  • Financial
  • Real Estate
  • Marketing
ncarol.com

'Spot Detective' – Check your spots this summer
ncarol.com/10200678

Trending...
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
The Spot Detective - who are they The Spot Detective - freckle
The latest campaign urging Australians to get their skin checked

MELBOURNE, Australia & SYDNEY - ncarol.com -- OncoBeta, a leading medical device company specialising in innovative epidermal radioisotope therapies for non-melanoma skin cancer, has launched The Spot Detective campaign to rally Australians in the fight against skin cancer this summer.

With two out of three Australians diagnosed with skin cancer before the age of 701, it is vital for all Australians to have regular skin checks. The Spot Detective campaign is encouraging Australians to visit a Spot Detective – their GP, dermatologist or skin health specialist – to have their spots assessed and to learn about the various treatments available for those diagnosed with non-melanoma skin cancer.

Skin cancer occurs when skin cells are damaged, often from overexposure to ultraviolet (UV) radiation from the sun. There are three main types of skin cancer: basal cell carcinoma (BCC); squamous cell carcinoma (SCC) and melanoma.2 Australia has one of the highest melanoma rates in the world1, with one Australian dying from melanoma every six hours.3 A skin check can save your life.

OncoBeta's Australian Medical Director, Dr Sam Vohra, says, "Thankfully most skin cancers are treatable and most of us will know someone who has had a skin cancer. Today, there are a range of treatments available to patients in addition to surgery, some of which are painless*, only needing a single session† and non-invasive."4-6

The Spot Detective campaign is asking Australians to take action: if they see a skin spot that is suspicious, new, oddly shaped or has changed in colour then it's time to get it checked. The campaign includes a series of LIVE reads across 2GB and WSFM in Sydney and 3AW and Gold 104.3 in Melbourne, as well as a social media and digital marketing campaign, and free skin check pop-ups at various locations.

More on ncarol.com
  • Food Journal Magazine Focuses Its Los Angeles Dining Coverage Across Three Editorial Verticals
  • Where Do Missouri Plane Crashes Really Happen? Not Where You'd Think
  • LCC Asia Pacific Sponsors CubeSatPlus 2026 at UNSW Sydney
  • The Sharon at SouthPark Breaks Ground on $178 Million Expansion
  • Pattern Recognition In The Arts

"With one of the highest incidences of skin cancer in the world, Australians need to be vigilant with their skin. The Spot Detective campaign is a timely reminder to make sure you are protecting yourself from the sun, and if you notice any changes to your skin, check in with a skin health specialist," added Dr Vohra.

Another health initiative from OncoBeta, this public awareness campaign also encourages anyone diagnosed with non-melanoma skin cancer to be well informed about all treatments and discuss their most suitable options with a healthcare professional. OncoBeta's skin cancer therapy which utilises the rhenium-188 isotope is now available at private clinics at Melbourne and Sydney. Patients with difficult anatomic localisations of a tumour, such as the ear, nose or anywhere on the face, and those with larger lesions problematic for plastic surgery, may benefit from this non-invasive solution.

To find out more information on skin cancer, and to learn what treatments are available, visit: www.spotdetective.com.au

About OncoBeta® GmbH
OncoBeta® GmbH, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Follow us on social media:

More on ncarol.com
  • Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
  • Couture Master Perfumer JoAnne Bassett Unveils All-Natural Parfum in Oil Collection in Gift Box
  • Independent Colbert Packaging Thrives Amid Industrywide Consolidation
  • Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

*No reported pain.3
†
Complete tumour regression in 98.5% of lesions treated.

References:
1. Cancer Council. Understanding Skin Cancer. January 2020. https://www.cancercouncil.com.au/ (accessed October 2022).
2. Skin Cancer. Available at https://www.mayoclinic.org/diseases-conditions/skin-cancer/symptoms-causes/syc-20377605 [Accessed October 2022]
3. Melanoma Institute Australia. Melamoma Facts. https://melanoma.org.au/about-melanoma/melanoma-facts/ (accessed October 2022).
4. Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48(5):1511–1521.
5. Cipriani C, et al. J Dermatol Treat. 2020; DOI: 10.1080/09546634.2020.1793890.
6. Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.

Contact
Jane Morey
***@moreymedia.com.au


Source: OncoBeta GmbH
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • LifeTime Asset & Tax Management Named on the 2026 Inc. 5000 List
  • Solid Earth Introduces RealtyID, a Universal Identity Spine for the Real Estate Industry
  • Pastor Miguel Bustillos Brings Deliverance and Exorcism Ministry Conference to Durham, NC
  • TOLI CORPORATION's President Visits U.S. to Celebrate Partnerships and Support North American Market
  • BumbleBeeSmart Launches Dedicated Sensory Wall Panels Collection for Adults, Memory Care and Senior Living
  • BlazeHive's AI SEO Agent Outranks Human Writers on 500+ Google Top-3 Results in 5 Months, on Autopilot
  • Priority Property Group Becomes Preferred Property Management Partner for Charlotte Investors
  • Inlow Upholstery Expands RV and Camper Upholstery Services in Western North Carolina
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
  • Phinge & CEO Robert DeMaio Publicly Declare Cash Settlements or Judgments Alone Cannot & Will Not Remedy the Deep Public Harm of Infringing Its IP
  • Dana Flanagan Expands the Authority Architect, Bringing a Nontraditional Approach to Executive Authority, Strategic Access and Business Growth
  • Phinge's Netverse: Reclaiming the Digital Frontier For Everyone Through CEO Robert DeMaio's Vision of a True App-less, User Data Sovereign World
  • DuraFast Label Company Launches Seiko SLP850 2" Thermal Printer with Free Label Promotion
  • Scientific Figure Releases Free Layout Template Libraries for Graphical Abstracts and Research Posters
  • Permian Museum announces the addition of an Ancient Alien Artifacts photo gallery
  • Lease A Sales Rep Rebands to Rent A Sales Rep
  • The Golden Jazz Fest Shuttle Returns for 2026
  • KeysCaribbean Resorts Offer Savings On Vacations Through Aug. 31, Preview Exceptional Select Fall Rates of Less Than $200/Night
  • Fit Body Boot Camp Launches Nationwide 'Fit Body Forever' Workshops to Help Adults 60+ Rebuild Strength and Prevent Falls
  • Canadian Aerospace Defence Talent Expo (CADTE) Launches National TalentThread Initiative to Strengthen Canada's Future Workforce
_catLbl0 _catLbl1

Popular on ncarol.com

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 268
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments - 134
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph - 131
  • Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home - 120
  • $620 Million in Recent Government Contract Awards with More Than $1.2 Billion in Annualized Revenue: Circle8 Group (N A S D A Q: CIRC) - 117
  • Opteamix welcomes Girish Ramachandra to its leadership team as Senior Vice President of Client Services - 108
  • New Research Identifies "The Great Junk Transfer": 49% of Americans Would Rather Inherit Nothing Than Sort Through a Relative's Belongings - 104
  • New ProEssentials v11: Native WinUI Charting Library, 100M Points in 15ms, Following Microsoft's Vision for True Native Swap-Chain Rendering - 102
  • RAS AP Consulting Expands Managed AP Governance™ Ecosystem, Launches Trademark Process, and Secures IFOL Speaker Invitation - 102
  • UK Financial Ltd Verifies Maya Preferred PRA Circulating Supply, Proving Its Eight-Year Promise of Under 1M Tokens After Chainlink Labs Agreement - 101

Similar on ncarol.com

  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man
  • The Sharon at SouthPark Breaks Ground on $178 Million Expansion
  • Couture Master Perfumer JoAnne Bassett Unveils All-Natural Parfum in Oil Collection in Gift Box
  • Independent Colbert Packaging Thrives Amid Industrywide Consolidation
  • Award-Winning Couture Master Perfumer JoAnne Bassett Launches All-Natural DIY Perfume Making Kits
  • Couture Master Perfumer JoAnne Bassett Offers Rare Opportunity to Acquire 70 Formula Perfume Codex
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute